AVDL News and Press, Avadel Pharmaceuticals plc From 05/11/20

Reported positive topline data from the pivotal Phase 3 REST-ON study Strengthened balance sheet with $190 million in gross proceeds from a private placement in February 2020 and public equity offering in May 2020   Reported revenue of $12.2 million for the first quarter of ...

For years, Jazz Pharmaceuticals ' (NASDAQ: JAZZ) success has been almost entirely dependent on that of Xyrem, a narcolepsy drug responsible for more than 70% of the company's revenue. The company's good fortune is likely to come to an end: Recently, Harmony Biosciences ,  Avadel Pharmac...

DUBLIN, Ireland, May 04, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced t...

Avadel Pharmaceuticals (NASDAQ: AVDL ) has filed a prospectus  for a 9.17M ADS from stockholders. More news on: Avadel Pharmaceuticals plc, Healthcare stocks news, , Read more ...

Avadel Pharmaceuticals (NASDAQ: AVDL ) has priced its public offering of ~11.6M American Depositary Shares (ADSs), each representing one ordinary share, at $10.75. Gross proceeds should be ~$125.0M. More news on: Avadel Pharmaceuticals plc, Healthcare stocks news, Stocks on the move, , ...

DUBLIN, Ireland, April 28, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced...

Jazz Pharmaceuticals (NASDAQ: JAZZ) has witnessed stellar growth of Xyrem for the treatment of narcolepsy since its launch. Sales of the product have amounted to over $1 billion and are increasing rapidly. The momentum , however, relies solely on the drug's market exclusivity, which may be ...

DUBLIN, Ireland, April 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced...

Gainers: Yield10 Bioscience (NASDAQ: YTEN ) +68% . More news on: Yield10 Bioscience, Inc., Aytu BioScience, Inc., Avadel Pharmaceuticals plc, Stocks on the move, , Read more ...

Shares of Avadel Pharmaceuticals (NASDAQ: AVDL) were skyrocketing 24.9% as of 11:19 a.m. EDT on Monday. The big jump came after the drugmaker announced positive results from a late-stage study evaluating the once-nightly sodium oxybate drug FT218 in treating excessive daytime sleepiness and ...